Companies

Roche

13 articles

Industry NewsRocheEndpoints News

Roche's divarasib cuts death risk 44% in a head-to-head against Amgen's and BMS's KRAS G12C drugs

  • At ESMO 2026 Roche detailed Krascendo 1, a Phase 3 comparing its next-generation KRAS G12C inhibitor divarasib with sotorasib or adagrasib in previously treated KRAS G12C-mutant non-small cell lung cancer.
  • Divarasib reduced the risk of death by 44% versus the two marketed drugs, per Endpoints News.
  • Earlier toplines had reported a progression-free survival win and no new safety signals.
PointsBased on public reports

A direct, randomized survival win over both approved G12C drugs is rare in oncology, where new agents usually rely on cross-trial comparisons. It gives Roche a strong claim on the second-line standard and puts pressure on Amgen and Bristol Myers Squibb, though the contest is moving to first line, where Revolution Medicines' RAS programs set the bar.

Industry NewsRoche / Poseida TherapeuticsBioSpace

Roche's Q3 pipeline cull ends Poseida's off-the-shelf CD19xCD20 CAR-T

  • Roche stopped RG6540, an allogeneic CD19xCD20 CAR-T from the Poseida acquisition; its lupus/MS study was withdrawn and a B-cell malignancy study terminated.
  • The cull also covers several early programs, including an Alzheimer's antisense drug and a geographic atrophy small molecule, and an atopic dermatitis study for afimkibart.
  • The CEO said Roche still backs CD19xCD20 CAR-T and merely stopped this molecule, pointing to other Poseida candidates; the myeloma asset RG6538 continues.
PointsBased on public reports

Poseida was bought for up to $1.5B largely to get off-the-shelf cell therapy for autoimmune disease, so shelving its lead autoimmune molecule stings. Roche's line that better CD19xCD20 successors exist is not yet visible in its published pipeline, so the autoimmune CAR-T thesis rests on molecules we haven't seen. Watch the next update for what replaces RG6540.

Industry NewsRocheBioPharma Dive

Roche's Q3 sales beat consensus, but guidance holds and top sellers face erosion

  • Group sales rose 7% to CHF 16.1B, ahead of consensus; one analyst called the beat cosmetic, helped by a new planning system. 2026 guidance was reaffirmed, not raised.
  • Xolair came in below estimates and a copycat launched in the US this month; Ocrevus, Tecentriq and Hemlibra face generics from 2030.
  • Roche flagged giredestrant (FDA decision by Dec. 18) and obesity as growth hopes and has signed six China licensing deals in two months.
PointsBased on public reports

Four of Roche's five top sellers are heading toward generic or biosimilar competition, which explains the dealmaking pace: eleven China licenses since early 2025 is a bet on buying replacement growth cheaply. Giredestrant enters a crowded endocrine-therapy field and obesity is a late start, so the 2027 growth story depends on execution rather than any single product.

Industry NewsRoche / ZymeworksEndpoints News

Roche takes worldwide rights to a Zymeworks trispecific T-cell engager

  • Roche will pay Zymeworks $55 million upfront for worldwide rights to a preclinical trispecific T cell engager.
  • Total potential value is up to $813 million.
  • Endpoints notes the molecule could go head-to-head with Amgen's Imdelltra.
PointsBased on public reports

A $55M upfront on an $813M headline for a preclinical asset is a standard option-style structure: Roche pays little until the molecule proves itself. The interesting angle is the benchmark, since pointing at Imdelltra implies a DLL3-type small cell lung cancer ambition. For Zymeworks it validates the multispecific platform without the cost of clinical development.

Industry NewsRoche / Hansoh PharmaFierce Biotech

Roche and Hansoh sign a second, much larger ADC collaboration

  • Roche and China's Hansoh signed a collaboration on a portfolio of early-stage antibody-drug conjugates, its second ADC deal after a 2025 CDH17 ADC license.
  • Reports put the upfront at about $400 million plus a further $110 million after a year, with total potential payments above $15 billion and royalties.
  • Hansoh leads early development through global phase 1a, after which Roche takes over development outside Greater China.
PointsBased on public reports

The structure is the story: a platform-style deal where the licensor runs the work through phase 1a looks like Roche buying options on China's early ADC output rather than a single asset. A headline above $15 billion is mostly back-end milestones, so the real signal is a near-$500 million near-term cash commitment. It also keeps Roche in the race with Merck, Pfizer and AstraZeneca for Chinese ADC supply.

Industry NewsRoche / Rona TherapeuticsFierce Biotech

Roche licenses Rona's ALK7-targeting RNAi obesity candidate in a deal worth up to $1.16B

  • Roche gets an exclusive license to Rona Therapeutics' investigational ALK7-targeting RNAi candidate for obesity.
  • Terms: up to $100M in upfront and near-term milestones, plus up to $1.06B in longer-term milestones and tiered royalties.
  • The program's codename and development stage were not disclosed.
PointsBased on public reports

ALK7 is the second hot RNAi obesity target after GSK's earlier SiranBio deal, and Roche says it wants to be a top-three obesity player, so this is portfolio-building on the cheap: small upfront, back-loaded milestones. It's also Roche's fifth deal with a Chinese drugmaker since late August, a sign that the best-priced early assets are still found there.

Industry NewsRoche / Defand TherapeuticsSTAT News

Roche signs molecular glue discovery deal with China's Defand Therapeutics

  • STAT reports Roche has signed a drug discovery deal with Chinese biotech Defand Therapeutics focused on molecular glue medicines.
  • Only the public lede of the STAT+ article could be read, so financial terms and targets are unverified here.
PointsBased on public reports

Roche keeps adding molecular glue partners rather than betting on one platform, and sourcing from Chinese biotechs fits the wider licensing trend. Without upfront and milestone figures I'd treat this as a discovery-stage option play, with the real signal being which targets and how many are named.

Industry NewsRoche / Chugai PharmaceuticalFierce Biotech

Roche Drops Emugrobart in Obesity After Interim Futility; Chugai Takes It Back

  • Roche ended obesity development of emugrobart (GYM329), an anti-latent-myostatin sweeping antibody meant to preserve muscle alongside GLP-1 therapy, after a Phase 2 GYMINDA interim analysis made meaningful weight loss unlikely.
  • Rights revert to Chugai, which is preparing to resume development in spinal muscular atrophy and is open to out-licensing; the antibody had already missed in SMA and FSHD trials in March.
PointsBased on public reports

This dents the muscle-preservation thesis in obesity: the pitch was that myostatin blockade adds lean-mass benefit on top of incretins, and this antibody didn't deliver. Other myostatin and activin-pathway programs will face sharper partner questions about what retained lean mass means clinically. A rights return usually signals a deprioritized asset, and a Phase 3 in SMA after an earlier SMA miss looks like a long shot.

Industry NewsIonis Pharmaceuticals / RocheEndpoints News

Sefaxersen Hits Primary Endpoint in Phase 3 IgA Nephropathy Trial, Opening Path to Accelerated Approval

  • Sefaxersen, Ionis's antisense oligonucleotide suppressing liver complement factor B, met the primary endpoint of Roche's Phase 3 IMAgINATION trial in high-risk primary IgA nephropathy.
  • A prespecified interim analysis of 459 patients (1:1 randomized) showed statistically significant, clinically meaningful proteinuria reduction (24-hour UPCR) vs. placebo at week 37.
  • The once-monthly, self-administered subcutaneous drug could support accelerated approval in a crowded IgAN market that already includes sparsentan.
PointsBased on public reports

Complement factor B suppression becomes a third distinct mechanism validated in IgA nephropathy, joining sparsentan's endothelin/AT1 blockade and the B-cell/APRIL plays from atacicept and sibeprenlimab; convergent proteinuria data across mechanisms suggests the market fragments by dosing convenience, not efficacy. Once-monthly self-injection undercuts daily oral and infused rivals on adherence, while Ionis banks another platform-licensing win validating its originate-and-out-license model.

Industry NewsRocheFierce Biotech

Roche's Enicepatide Hits Phase II Goals in Diabetes and Obesity Trial

  • Enicepatide (CT-388), Roche's dual GLP-1/GIP receptor agonist, met both primary endpoints in a Phase II trial in type 2 diabetes with overweight or obesity.
  • At 48 weeks, the top 24 mg dose drove dose-dependent weight loss near 15% with no plateau, plus strong glycemic improvement.
  • Most high-dose patients reached near-normal HbA1c, and Roche is now advancing Phase III programs (ENITH-1, ENITH-2) plus a glycemic-control study.
PointsBased on public reports

Roche just cashed in its $2.7B Carmot acquisition: a 15% weight-loss curve still climbing at 48 weeks puts enicepatide in contention with Lilly's retatrutide and Novo's CagriSema, not just chasing tirzepatide. More importantly, it hands Roche a credible re-entry into metabolic disease after sitting out the incretin boom — Phase III now becomes the real test of manufacturing and commercial scale-up against entrenched leaders.

Industry NewsRoche / Medicines Patent PoolSTAT News

Roche Flu Drug Xofluza Cleared for Generic Production Under Pandemic-Prep Deal

  • The Medicines Patent Pool signed sub-licensing deals with 11 generic manufacturers to produce Roche's flu antiviral Xofluza (baloxavir marboxil).
  • The agreements, building on MPP's broader license with Roche, cover supply to roughly 129 low- and middle-income countries and include technical support for regulatory approval.
  • They also carry pandemic-specific provisions meant to ease supply, territory and royalty constraints if a global flu outbreak occurs.
PointsBased on public reports

Roche is front-running compulsory-licensing pressure here, not waiting for a pandemic to force its hand the way COVID access fights forced others — cheap reputational insurance bought years early. But 11 sub-licensees on paper isn't surge capacity: without tech-transfer and validation runs now, that capacity stays theoretical until an outbreak tests it. Still, MPP's Xofluza network beats what Gilead ever built for oseltamivir — a real bar-raise on pandemic-prep licensing.

Industry NewsRoche / GenentechSTAT News

Roche Opens New Innovation Center in Boston Focused on Cardiovascular, Renal and Metabolic Research

  • Roche and Genentech held the grand opening of the Roche Genentech Innovation Center Boston, located at Harvard's Enterprise Research Campus in Allston, Massachusetts.
  • The 95,000-square-foot facility is leased for 10 years and can accommodate up to 500 employees.
  • It will serve as Roche's hub for Cardiovascular, Renal and Metabolic (CVRM) disease research, spanning discovery research, clinical development, and AI/data science.
  • The center is designed to provide an end-to-end R&D presence in CVRM, from early discovery through late-stage clinical development.
  • The opening forms part of Roche and Genentech's broader $50 billion commitment to U.S. manufacturing and R&D investment, alongside recent expansions in Holly Springs, North Carolina, and Hillsboro, Oregon.
PointsBased on public reports

Roche is planting 500 seats squarely in cardiometabolic territory that Novo Nordisk and Eli Lilly currently own by revenue, valuation, and narrative — that's the real story here, not the ribbon-cutting. Roche's own GLP-1/amylin assets (CT-388, petrelintide) are still early and have yet to prove they can compete on efficacy or tolerability — a shiny 95,000-square-foot building doesn't change that math. Read the CVRM bet as portfolio triage as much as ambition: consolidating discovery-through-clinical talent in one hub is what you do when you need faster kill/advance decisions, not just more capacity. And the timing — loud US R&D investment amid tariff and reshoring pressure — reads as much like government-relations optics tied to the $50B pledge as it does science strategy. The signal worth tracking is a phase 2/3 readout from this hub, not the lease signing itself.

Industry NewsRoche / Simcere ZaimingFierce Biotech

Roche's China Buying Spree Continues With $1.53B Simcere Antibody Deal

  • Roche will pay Simcere Zaiming $75M upfront for exclusive global rights to SIM0660, with up to $1.53B in total milestones plus tiered double-digit royalties.
  • SIM0660 is a preclinical trispecific antibody combining a CD3 T-cell-engaging arm with two B-cell-targeting arms against CD79a and CD19.
  • Dual B-cell antigen targeting is designed to broaden coverage across malignant and autoimmune B-cell populations, including patients who progressed on CD20- or CD19-directed therapies.
  • A cytokine-limiting design aims to address the tolerability issues that have dogged earlier T-cell engagers.
  • The deal is Roche's third Chinese in-licensing agreement in just over a week, extending a multi-year pattern of sourcing early-stage oncology and immunology assets from Chinese biotechs.
PointsBased on public reports

Dual-antigen targeting (CD79a + CD19) is the differentiator — most B-cell engagers still chase one antigen, so this asset is explicitly built for patients who've already progressed on CD19- or CD20-directed therapy, a relapse population CAR-T and existing bispecifics can't fully cover. $75M upfront against $1.53B in milestones is textbook preclinical pricing: Roche caps its downside, Simcere Zaiming carries the early clinical risk, and most of the payout hinges on the cytokine-limiting design actually solving the tolerability problem that's dogged prior T-cell engagers. Three China deals in barely a week isn't bargain-hunting — it's a systematic pipeline-refill strategy, treating Chinese biotech as a faster, cheaper source of differentiated immuno-oncology chemistry than internal discovery. As more Western majors chase this playbook, though, China-originated multispecifics could get crowded and bid up before any clear pivotal data emerges.